Alice L. Fong

Family Medicine
10800 Magnolia Ave Rm C-5
Riverside, CA 92505

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications

Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review.

Safety and tolerability of astegolimab, an anti-ST2 monoclonal antibody: a narrative review.

Journal: Respiratory research
Published: April 16, 2025

Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies.

Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti-ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies.

Journal: Clinical and translational science
Published: March 11, 2025

Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.

Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.

Journal: Allergy
Published: March 01, 2024

A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.

A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.

Journal: Pulmonary pharmacology & therapeutics
Published: March 22, 2021

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.

Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.

Journal: The Journal of allergy and clinical immunology
Published: January 03, 2021

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.

Journal: BMC pulmonary medicine
Published: August 28, 2018
Showing 1-6 of 6

Last Updated: 09/26/2026